Open House Discount Agreements for Colecalciferol (Non-RX) Prescription Products According to Annex 1 AM-RL G-BA, ATC A11CC05
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Colecalciferol, non RX, ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte, ATC A11CC05
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
Open-house agreements may be automatically terminated if other discount agreements for Colecalciferol are concluded in...
No minimum volume or revenue guarantee; actual sales depend on prescription behavior.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Supply of Colecalciferol (Vitamin D3) products (non-RX, prescription products according to Annex 1 AM-RL G-BA, ATC A11CC05)
- Non-exclusive discount agreements under § 130a Abs. 8 SGB V with AOK Bayern
Show full summary
Open-house model for non-exclusive discount agreements on Colecalciferol (non-RX) products for AOK Bayern. All qualified pharmaceutical companies can join. Contracts run from 01/03/2025 to 28/02/2027. No competitive selection; contracts are awarded to all interested and eligible participants.
Risks
Open-house agreements may be automatically terminated if other discount agreements for Colecalciferol are concluded in...
No minimum volume or revenue guarantee; actual sales depend on prescription behavior.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
Administrative
- Submission of signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of signed contract and appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Discount Agreements for Colecalciferol (Non-RX) Prescription Products According to Annex 1 AM-RL G-BA, ATC A11CC05
Non-exclusive discount agreements for Colecalciferol (Vitamin D3) products, non-RX, prescription products according to Annex 1 AM-RL G-BA. Supply of pharmaceutical products under § 130a Abs. 8 SGB V. Any pharmaceutical company meeting eligibility can join. Contracts are identical and non-negotiable.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Colecalciferol, non RX, ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte, ATC A11CC05
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 16 Jan 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 33054-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
Open-house agreements may be automatically terminated if other discount agreements for Colecalciferol are concluded in...
No minimum volume or revenue guarantee; actual sales depend on prescription behavior.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications